对于抗性高血压的脏缩:对当前文献的综述
Aparna Iyer1, Shim Roh1, Haris Muhammad1
1Englewood Hospital and Medical Center, Department of Medicine, 350 Engle St, Englewood, NJ 07631, USA.
概括
抗性高血压,不受控制的高血压,可以通过脏缩 (RDN) 来治疗. 这种手术向交感神经系统,降低血压并减少心血管风险.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 干预心脏病学 干预心脏病学
背景情况:
- 抗性高血压影响10%的高血压患者,增加心血管事件的风险.
- 它被定义为血压 (BP) 仍然升高,尽管治疗≥3抗高血压剂,包括利尿剂.
研究的目的:
- 本综述探讨了脏缩 (RDN) 作为抗性高血压的治疗方法.
- 它检查了RDN的机制,历史,进步,证据和指导方针.
主要方法:
- 审查关于脏皮损伤的现有文献.
- 临床试验和程序发展的分析.
- 讨论当前的指导方针和未来的研究.
主要成果:
- RDN调节交感神经系统以降低血压.
- 最近的进展显示了提高效率和安全性的前景.
- 临床证据支持RDN在抵抗性高血压的血压控制中的作用.
结论:
- 脏缩是一种对抗性高血压的有前途的干预策略.
- 需要进一步的研究和指导方针的完善,以优化其应用.
- 在受影响的患者中,RDN可能会显著降低心血管风险.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
526
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
526
Antihypertensive Drugs: Direct Renin Inhibitors
849
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
849
Antihypertensive Drugs: Angiotensin II Receptor Blockers
950
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
950
Antihypertensive Drugs: Vasodilators
660
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
660
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
913
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
913
Heart Failure Drugs: Diuretics
505
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
505


